@VPrasadMDMPH Not true. Our target trial emulation on tocilizumab, published in mid 2020, was validated by multiple RCTs in 2021. https://t.co/GyiouGrctu
@zacharylipton 2) Tocilizumab as an early treatment after covid-related hospitalization. Was first estimated in here [5] late 2020, and an RCT showed very similar results in an RCT mid 2021 [6] [5] https://t.co/PUNLuupKQK [6] https://t.co/tOcT4R2YYL
RT @ABsteward: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 STOP-COVID https://t.co/skt45vg…
@drjohnm Our observational study on tocilizumab in ICU patients w/COVID-19 (criticized by some on this thread at the time for being observational), confirmed by multiple RCTs. https://t.co/GyiouGrKj2
@spkalantri @AnantBhan From the “risk of death” CI’s upper bound (.92), it would appear you needed to treat 13 patients with Tocilizumab to record 1 life as being saved https://t.co/r4iiZO7OQZ
@dnunan79 There are cases where observational data provide strong evidence then confirmed by RCT. E.g tocilizumab. https://t.co/Q9GUJn2vVj Maybe tenofivir will turn out the same way. https://t.co/JMFFlZvpKg
Anand Srivastava, MD, and colleagues aimed to test whether tocilizumab decreases mortality in this population. Read more: https://t.co/ztfPW7i78u
Global updates in intensive care, curated by Concord Biotech. #GlobalUpdates #intensivecare #antifungal https://t.co/WJ0b0EZWuy https://t.co/7bRym4rX95 https://t.co/G162CZzn4i https://t.co/my9zrwWT1y https://t.co/z43jWpeRxA
RT @Alejand22697798: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/LY4rOZap48 vía…
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/LY4rOZap48 vía @JAMAInternalMed part of @JAMANetwork
RT @jcperezpons: Tocilizumab en #SARS_CoV_2 mejor antes de la ingresar en UCI
Tocilizumab en #SARS_CoV_2 mejor antes de la ingresar en UCI
El artículo de @NEJM aclara los factores de confusión (confounders) mencionados en @JAMA_current https://t.co/yNsTdoEjwT https://t.co/wQqnRjgMLQ
@dscharpfMD Hmmm 🤔 Es gab bereits vier andere Studien, wo Tocilizumab nicht überzeugen konnte. https://t.co/p68oO0pJ83 https://t.co/n4eb0EpvSy https://t.co/OslGlFqSGH https://t.co/fjwVcY8sWw https://t.co/nGBv0k8LHB
Anand Srivastava, MD, and colleagues studied 3924 patients, and found that the risk of in-hospital death was estimated to be lower with tocilizumab treatment in the first 2 days of intensive care unit admission compared with no early use of tocilizumab. ht
Is early treatment with tocilizumab associated with a lower mortality rate among critically ill patients with COVID-19? https://t.co/1TSCskVVgN
RT @JAMAInternalMed: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/mnzjo63uAb
RT @FredLAFernandes: Referências para quem quiser aprofundar: https://t.co/9i2eiXSQkg https://t.co/Q7VHbcuAXj https://t.co/ms4aGMXNzj
RT @JAMAInternalMed: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/mnzjo63uAb
RT @JAMAInternalMed: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/mnzjo63uAb
RT @JAMAInternalMed: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/mnzjo63uAb
RT @JAMAInternalMed: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/mnzjo63uAb
RT @JAMAInternalMed: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/mnzjo63uAb
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/mnzjo63uAb
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
RT @ventilacionmeca: Tociluzumab precoz en paciente COVID-19. Ojo estudio de cohorte. Pendientes de ensayos clinicos
日本の臨床試験の結果も気になるところです。
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
RT @ventilacionmeca: Tociluzumab precoz en paciente COVID-19. Ojo estudio de cohorte. Pendientes de ensayos clinicos
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
RT @ventilacionmeca: Tociluzumab precoz en paciente COVID-19. Ojo estudio de cohorte. Pendientes de ensayos clinicos
RT @ventilacionmeca: Tociluzumab precoz en paciente COVID-19. Ojo estudio de cohorte. Pendientes de ensayos clinicos
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
RT @ventilacionmeca: Tociluzumab precoz en paciente COVID-19. Ojo estudio de cohorte. Pendientes de ensayos clinicos
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
RT @ventilacionmeca: Tociluzumab precoz en paciente COVID-19. Ojo estudio de cohorte. Pendientes de ensayos clinicos
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
Tociluzumab precoz en paciente COVID-19. Ojo estudio de cohorte. Pendientes de ensayos clinicos
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality w…
In a cohort study of 3924 critically ill adults w #COVID19 admitted to ICUs at 68 hospitals across the US, mortality was 30% lower in patients treated with tocilizumab in the first 2 days of ICU admission compared to patients not treated with tocilizumab h
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. https://t.co/Ktk4MIkk8s
RT @FredLAFernandes: Referências para quem quiser aprofundar: https://t.co/9i2eiXSQkg https://t.co/Q7VHbcuAXj https://t.co/ms4aGMXNzj
RT @orangeapo: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/f2g16YvTWx @JAMAInte…
RT @orangeapo: Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/f2g16YvTWx @JAMAInte…
RT @lastweekinmed: in this retrospective cohort study of critically ill patients with #COVID19, the risk of in-hospital mortality was lower…
in this retrospective cohort study of critically ill patients with #COVID19, the risk of in-hospital mortality was lower in patients treated with #tocilizumab in the first 2 days of ICU admission compared with patients who received usual care. #medtwitter
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/f2g16YvTWx @JAMAInternalMed part of @JAMANetworkより
RT @FredLAFernandes: Referências para quem quiser aprofundar: https://t.co/9i2eiXSQkg https://t.co/Q7VHbcuAXj https://t.co/ms4aGMXNzj
RT @FredLAFernandes: Referências para quem quiser aprofundar: https://t.co/9i2eiXSQkg https://t.co/Q7VHbcuAXj https://t.co/ms4aGMXNzj
RT @FredLAFernandes: Referências para quem quiser aprofundar: https://t.co/9i2eiXSQkg https://t.co/Q7VHbcuAXj https://t.co/ms4aGMXNzj
RT @FredLAFernandes: Referências para quem quiser aprofundar: https://t.co/9i2eiXSQkg https://t.co/Q7VHbcuAXj https://t.co/ms4aGMXNzj
RT @FredLAFernandes: Referências para quem quiser aprofundar: https://t.co/9i2eiXSQkg https://t.co/Q7VHbcuAXj https://t.co/ms4aGMXNzj
RT @FredLAFernandes: Referências para quem quiser aprofundar: https://t.co/9i2eiXSQkg https://t.co/Q7VHbcuAXj https://t.co/ms4aGMXNzj
RT @FredLAFernandes: Referências para quem quiser aprofundar: https://t.co/9i2eiXSQkg https://t.co/Q7VHbcuAXj https://t.co/ms4aGMXNzj
RT @FredLAFernandes: Referências para quem quiser aprofundar: https://t.co/9i2eiXSQkg https://t.co/Q7VHbcuAXj https://t.co/ms4aGMXNzj
RT @FredLAFernandes: Referências para quem quiser aprofundar: https://t.co/9i2eiXSQkg https://t.co/Q7VHbcuAXj https://t.co/ms4aGMXNzj
Referências para quem quiser aprofundar: https://t.co/9i2eiXSQkg https://t.co/Q7VHbcuAXj https://t.co/ms4aGMXNzj
(JAMA Intern Med) Mortalidad en pac con #COVID19 tratados con tocilizumab https://t.co/7FLkGWYuKu Est Observ https://t.co/tmdZvliJpc ECA https://t.co/Z2KuvjdChW Editorial https://t.co/Mvg9PXkJcR
@alsnig @luisadolores68 Hay ya resultados. Pero han sido ni suficientes. Dejo ejemplo 👇🏼 https://t.co/NAYR7Vam8n
Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 https://t.co/PAJ78JEeAN via @JAMAInternalMed part of @JAMANetwork
12-20-2020: The 3 U.S. meta-analyses: Aziz, Boregowda, Kaye. Head MDs for 20 U.S. pro-Actemra studies: Antony, Biran, Chilimuri, Gupta, Ip, Jordan, Kaminski, Kewan, Ladna, Lewis, Melveedu, Mo, Norain, Oliva, Petrak, Price, Salama, Singh, Somers, Strohbehn
RT @JAMAInternalMed: In a cohort study of 3924 critically ill adults with #COVID19 admitted to ICUs at 68 hospitals across the US, mortalit…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
A little hope on the horizon for treatment.... Science is working. It takes time. Let's hunker down a bit longer until we have a triple threat of rapid testing, vaccines and treatments.
Preuves cliniques pour un traitement Covid (tocilizumab, un immunosuppresseur contre la polyarthrite). NB: c'est aussi la piste privilégiée par des équipes APHP dès avril, en toute discrétion pendant que les polémiques autour de Raoult ou de remdesivir o
Good news today from the #REMAP trial confirms observational evidence that tociluzumab works. The results also provide more evidence that careful & well-conducted observational data analyses can help us get good answers faster.
RT @atscommunity: Association between early treatment with tocilizumab and mortality among critically ill patients with #COVID19: https://t…
RT @sefh_: En últimas semanas 4 artículos de #Tocilizumab en diferentes fases #COVID19 ➡️ NO papel claro como tto (poco o ningún beneficio)…
RT @atscommunity: Association between early treatment with tocilizumab and mortality among critically ill patients with #COVID19: https://t…
RT @atscommunity: Association between early treatment with tocilizumab and mortality among critically ill patients with #COVID19: https://t…
RT @atscommunity: Association between early treatment with tocilizumab and mortality among critically ill patients with #COVID19: https://t…
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19 | Critical Care Medicine | JAMA Internal Medicine | JAMA Network https://t.co/fVOUKJpsIz
RT @atscommunity: Association between early treatment with tocilizumab and mortality among critically ill patients with #COVID19: https://t…
RT @atscommunity: Association between early treatment with tocilizumab and mortality among critically ill patients with #COVID19: https://t…
Association between early treatment with tocilizumab and mortality among critically ill patients with #COVID19: https://t.co/h3OEJyY3Vr